Sam Brusco, Associate Editor06.25.24
Moximed has appointed Christopher Gleason as its new president and CEO.
Most recently, Gleason was VP of sales at Relievant, which was acquired by Boston Scientific for $850 million late last year. He also previously served as VP of interventional urology sales at Teleflex and other sales leadership positions at NeoTract before it was acquired by Teleflex in 2017.
Gleason was also in leadership roles at Xenex Healthcare and Acclarent at Johnson & Johnson.
“It is an honor to join Moximed as we expand access of the MISHA Knee System to the many knee OA patients in the U.S. who may benefit,” said Gleason. “I have spoken to a number of patients, and I’m inspired by the amazing stories of how the MISHA Knee System has positively impacted their lives. We have a talented team who is relentlessly dedicated to advancing patient care, and I look forward to helping Moximed realize its tremendous potential.”
Moximed announced it had completed its first commercial cases with the MISHA implantable shock absorber for patients with medial knee osteoarthritis (OA) last September. The Fremont, Calif.-based company also welcomed new chief financial and strategy officer James Leech earlier this year.
“I’m thrilled to have Chris take the leadership role at Moximed and drive the expansion phase of the company,” said Moximed co-founder and chief technology officer Anton Clifford, Ph.D. “We’re seeing tremendous clinical results from commercial use of the MISHA Knee System, and it’s the perfect time for Chris to broaden our commercial reach and enable greater product access for the benefit of patients.”
Most recently, Gleason was VP of sales at Relievant, which was acquired by Boston Scientific for $850 million late last year. He also previously served as VP of interventional urology sales at Teleflex and other sales leadership positions at NeoTract before it was acquired by Teleflex in 2017.
Gleason was also in leadership roles at Xenex Healthcare and Acclarent at Johnson & Johnson.
“It is an honor to join Moximed as we expand access of the MISHA Knee System to the many knee OA patients in the U.S. who may benefit,” said Gleason. “I have spoken to a number of patients, and I’m inspired by the amazing stories of how the MISHA Knee System has positively impacted their lives. We have a talented team who is relentlessly dedicated to advancing patient care, and I look forward to helping Moximed realize its tremendous potential.”
Moximed announced it had completed its first commercial cases with the MISHA implantable shock absorber for patients with medial knee osteoarthritis (OA) last September. The Fremont, Calif.-based company also welcomed new chief financial and strategy officer James Leech earlier this year.
“I’m thrilled to have Chris take the leadership role at Moximed and drive the expansion phase of the company,” said Moximed co-founder and chief technology officer Anton Clifford, Ph.D. “We’re seeing tremendous clinical results from commercial use of the MISHA Knee System, and it’s the perfect time for Chris to broaden our commercial reach and enable greater product access for the benefit of patients.”